论文部分内容阅读
目的 通过检测血清层粘蛋白 (LN)、透明质酸 (HA)及脯氨酸肽酶 (PLD)评价其在肝硬化早期防治的临床价值。方法 用酶联免疫法检测 2 66例肝病患者。 (其中急性肝炎 46例 ,慢性肝炎 13 6例 ,肝硬化 84例 )血清层粘蛋白、透明质酸及脯氨酸肽酶 ,并将三者进行比例分析。结果 与正常血清比较 ,急性肝炎患者其血清中LN、HA、PLD的含量无明显的正相关 (P >0 .0 5 ) ;慢性肝炎患者其血清中LN、HA、PLD的含量呈明显的正相关 (P <0 .0 5 ) ;肝硬化患者其血清中LN、HA、PLD的含量呈极显著的正相关 (P <0 .0 1)。结论 检测血清层粘蛋白、透明质酸及脯氨酸肽酶对肝硬化早期的防治具有重要的临床意义。
Objective To evaluate the clinical value of serum laminin (LN), hyaluronic acid (HA) and prolyl peptidase (PLD) in the prevention and treatment of early cirrhosis. Methods Enzyme linked immunosorbent assay was used to detect 666 cases of liver disease. (Including 46 cases of acute hepatitis, 136 cases of chronic hepatitis and 84 cases of liver cirrhosis), and the proportion of serum hyaluronic acid and proline peptidase were calculated. Results There was no significant positive correlation between serum levels of LN, HA and PLD in patients with acute hepatitis (P> 0.05). Serum levels of LN, HA and PLD in patients with chronic hepatitis were significantly positive (P <0.05). There was a significant positive correlation between serum levels of LN, HA and PLD in patients with cirrhosis (P <0.01). Conclusion Detection of serum laminin, hyaluronic acid and prolyl peptidase has important clinical significance in the early prevention and treatment of cirrhosis.